

International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis

Editors:

Pedro Vieira-Baptista, Colleen K. Stockdale, Jack Sobel



March 2023

Cite document as:

Vieira-Baptista P, Stockdale CK, Sobel J (eds). *International Society for the Study of Vulvovaginal Disease recommendations for the diagnosis and treatment of vaginitis*. Lisbon: Admedic, 2023

ISBN: 978-989-53489-3-0

Legal deposit: 512780/23

DOI: <https://doi.org/10.59153/adm.rdtv.001>

Property

ISSVD

www.issvd.org

Edition & Pagination

Ad Médic, Lda.

www.admedic.pt

Published March 2023

This publication was inspired by the goals and mission of the International Society for the Study of Vulvovaginal Disease (ISSVD) which are:

- to promote international communication among gynecologists, pathologists, dermatologists, and other healthcare providers;
- to establish international agreement on terminology and definitions of vulvovaginal diseases;
- to promote clinical investigation, basic research and dissemination of knowledge in this field.

Visit www.issvd.org for more information.

INDEX

Authors	13
Preface	17
Note	18
CHAPTER 1 – The normal discharge	21
1.1 The vaginal microbiome and other components of the normal discharge	21
Host cell components	22
Soluble components and mucus	23
Microorganisms	23
Bacteria	23
Viruses	24
Yeasts	25
1.2 Normal vaginal discharge variations during the menstrual cycle	25
1.3 Normal vaginal discharge in physiological estrogen deficiency (pre-menstrual girls, postpartum, and post-menopausal women)	26
1.4 Normal vaginal discharge during pregnancy	28
1.5 Factors contributing to variations in the composition of the vaginal discharge	28
Stress	28
Sexual activity	28
Douching	29
Smoking	29
Diet	29
1.6 Racial differences in the composition of the vaginal discharge and vaginal microbiota	29
1.7 Summary and conclusions	30
Recommendations	30
References	30
CHAPTER 2 – Diagnostic tools	37
2.1 Introduction	37
2.2 pH	37
2.3 Whiff test	39
2.4 Wet mount microscopy	39
2.5 Gram and other staining techniques	44
2.6 Cultures	46
2.7 Amsel criteria	46
2.8 Enzymatic tests	48
2.9 Molecular tests	49
Recommendations	53

References	55
CHAPTER 3 – Bacterial vaginosis	61
3.1 Introduction	61
3.2 Etiology and physiopathology	62
3.3 Prevalence and epidemiology	63
Global and regional estimates of bacterial vaginosis prevalence	63
Bacterial vaginosis prevalence among pregnant women	64
Bacterial vaginosis prevalence among other populations/sub-groups of women	64
3.4 Risk factors	65
3.5 Complications	66
Preterm birth	66
Endometritis/ postpartum fever	66
Post hysterectomy vaginal cuff cellulitis	67
Post abortal infection	67
Pelvic inflammatory disease	67
Other sexually transmitted infections	67
3.6 Signs and symptoms	67
3.7 Diagnosis	68
Clinical diagnosis	69
Gram-stain diagnosis	70
Cultures	71
Point-of-care tests (non-molecular)	71
Molecular diagnostics	72
Differential diagnosis	72
3.8 Treatment	73
The principles of treatment for non-pregnant women; drug selection, dosing, adverse effects, and efficacy	74
Oral versus vaginal treatment	74
Metronidazole	74
Clindamycin	74
Overview of second-line and alternative treatments	75
Dequalinium chloride	75
Tinidazole	75
Secnidazole	76
Focused assessments of experimental/investigational treatments	76
Efficacy of probiotics for bacterial vaginosis treatment	76
Follow-up	76
Treatment regimens during pregnancy and lactation	76
Special considerations	77

Counseling-supportive management in infertile women attending fertility treatment	77
Screening and treatment of asymptomatic bacterial vaginosis in pregnancy	77
Approache to preoperative screening strategies for bacterial vaginosis	77
Management of sexual partners	77
Management of recurrent and refractory bacterial vaginosis	78
3.9 Special situations	80
Infancy	80
Postmenopausal women	80
Immunosuppression	81
Bacterial vaginosis in pregnancy	81
3.10 Future perspectives	82
Recommendations	83
References	84
CHAPTER 4 – Candidiasis	95
4.1 Introduction	95
4.2 Etiology and pathophysiology	95
4.3 Prevalence and epidemiology	96
4.4 Risk factors	97
4.5 Classification of vulvovaginal candidiasis	97
Severe infections	98
Recurrent infections	98
Non- <i>albicans Candida</i> infections	98
4.6 Signs and symptoms	99
4.7 Diagnosis	100
4.8 Treatment of vulvovaginal candidiasis	102
Asymptomatic colonization	102
Uncomplicated vulvovaginal candidiasis	102
Recurrent vulvovaginal candidiasis due to <i>C. albicans</i>	103
Non- <i>albicans Candida</i> vulvovaginitis	104
4.9 Special situations	104
Prepubertal children	104
Pregnancy	105
Postpartum and breastfeeding mothers	105
Menopause	105
Immunosuppression	106
4.10 Future perspectives	106
Recommendations	107
References	108

CHAPTER 5 – Trichomoniasis	113
5.1 Introduction	113
5.2 Etiology and pathophysiology	113
5.3 Prevalence and epidemiology	115
5.4 Risk factors	115
5.5 Complications	116
Adverse birth outcomes	116
Risk of HIV	117
Risk of other sexually transmitted infections	118
Pelvic inflammatory disease	118
Infertility	118
Risk of cervical cancer	118
5.6 Signs and symptoms	119
5.7 Diagnosis	119
5.8 Treatment and follow-up	122
5.9 Special situations	123
Infants	123
Pregnant and lactating women	123
5-nitroimidazole hypersensitivity	123
Persistent <i>T. vaginalis</i> infection	124
HIV-infected women	125
Partner management	125
5.10 Future perspectives	125
Recommendations	126
References	127
CHAPTER 6 – Cytolytic vaginosis, lactobacillosis and leptothrix	133
6.1 Introduction	133
6.2 Cytolytic vaginosis	133
Prevalence and epidemiology	134
Risk factors	134
Complications	134
Signs and symptoms	134
Diagnosis	134
Treatment	135
Special situations (infancy, pregnancy, postpartum/breastfeeding, menopause, immunosuppression)	136
Future perspectives	136
6.3 Leptothrix	136
Prevalence and epidemiology	137

Risk factors	137
Complications	137
Signs and symptoms	138
Diagnosis	138
Treatment	139
Special situations (infancy, pregnancy, postpartum/breastfeeding, menopause, immunosuppression)	140
6.4 Future perspectives	140
Recommendations	140
References	140
CHAPTER 7 – Aerobic vaginitis/desquamative inflammatory vaginitis	143
7.1 Introduction	143
7.2 Etiology and pathophysiology	144
7.3 Prevalence and epidemiology	145
7.4 Risk factors	145
7.5 Complications	145
7.6 Signs and symptoms	146
7.7 Diagnosis	147
7.8 Treatment	148
7.9 Special situations (pregnancy, postpartum/breastfeeding)	150
7.10 Future perspectives	151
Recommendations	151
References	152
CHAPTER 8 – Vulvovaginal atrophy	157
8.1 Introduction	157
8.2 Etiology and pathophysiology	157
8.3 Prevalence and epidemiology	158
8.4 Complications	159
8.5 Signs and symptoms	159
8.6 Diagnosis	160
8.7 Treatment	162
Vaginal lubricants and moisturizers	162
Estrogen (systemic and vaginal) and selective estrogen receptor modulator therapy	163
Vaginal androgen (testosterone) therapy	164
Vaginal dehydroepiandrosterone (prasterone) therapy	165
Vaginal LASER	165
Vaginal radiofrequency	166
Pelvic floor rehabilitation	166
8.8 Special situations (postpartum/breastfeeding, breast cancer)	166

8.9 Future perspectives	167
Recommendations	168
References	168
CHAPTER 9 – Vaginitis in children	173
9.1 Introduction	173
9.2 The vagina in the prepubertal child	173
The vestibule	173
The hymen	173
The vagina and vaginal discharge	174
9.3 How to conduct a vaginal examination in a child	175
9.4 Testing for infection	176
9.5 Vaginal discharge	176
Vaginal discharge due to infection	176
Bacterial vaginitis	176
Introduction	176
Prevalence	177
Etiology and pathophysiology	177
Risk factors	177
Signs and symptoms	177
Diagnosis	177
Treatment	178
Pinworms/threadworms	178
Introduction	178
Etiology and pathophysiology	178
Prevalence	179
Risk Factors	179
Signs and symptoms	179
Diagnosis	179
Treatment	179
Candidiasis	179
Bacterial vaginosis	180
Other infections producing vaginitis	180
Vaginal foreign bodies	181
Introduction	181
Etiology and pathophysiology	181
Prevalence	181
Signs and Symptoms	181
Diagnosis	181
Treatment	182

9.6 Dermatoses and dermatitis which involve the vagina	182
Recommendations	182
References	183
CHAPTER 10 – Probiotics, prebiotics and synbiotics for vaginitis	185
10.1 Introduction	185
10.2 Bacterial vaginosis	186
Probiotics	186
Probiotics for bacterial vaginosis in pregnancy	188
Prebiotics and synbiotics	188
Clinical recommendations	189
10.3 Vulvovaginal candidiasis	189
Probiotics	189
Prebiotics and synbiotics	190
Clinical recommendations	190
10.4 Aerobic vaginitis/desquamative inflammatory vaginitis	190
Probiotics	190
Prebiotics and synbiotics	191
Clinical recommendations	191
10.5 Trichomoniasis	191
Probiotics	191
Prebiotics and synbiotics	192
Clinical recommendations	192
10.6 Conclusion	192
Recommendations	192
References	193

INDEX OF FIGURES

FIGURE 1.1 Normal vaginal discharge. A – wet mount microscopy (400x, phase contrast) B – Gram stain (1000x, oil immersion)	21
FIGURE 1.2 Wet mount microscopy of a vaginal sample collected from a breastfeeding woman (400x, phase contrast).	27
FIGURE 2.1 Vaginal pH measurement.	38
FIGURE 2.2 Wet mount microscopy (400x, phase contrast). A– normal B– bacterial vaginosis C– candidiasis D– trichomoniasis E– cytolytic vaginosis F– leptothrix G– desquamative inflammatory vaginitis (severe aerobic vaginitis) H– vaginal atrophy	40
FIGURE 2.3 Wet mount microscopy (400x); granular microbiota suggestive of bacterial vaginosis. A– without phase contrast B– with phase contrast	41
FIGURE 2.4 Sampling of vaginal discharge for wet mount microscopy.	41
FIGURE 2.5 Wet mount microscopy with phase contrast (400x) showing the presence of a “mixed infection” (<i>Candida</i> spp. and bacterial vaginosis).	48
FIGURE 3.1 Typical discharge associated with bacterial vaginosis.	68
FIGURE 3.2 Wet mount microscopy (400x, phase contrast). A–C– bacterial vaginosis: absence of lactobacilli, granular microbiota and presence of clue cells (seen in A)	69
FIGURE 3.3 Gram stain (1000x, oil immersion). A and B– Bacterial vaginosis	70
FIGURE 4.1 Acute vulvovaginal candidiasis. Exteriorization of white “cheesy” discharge, vulvar erythema and edema.	99
FIGURE 4.2 Acute vulvovaginal candidiasis. Erythema and fissures of the intelabial <i>sulci</i> .	99
FIGURE 4.3 Acute vulvovaginal candidiasis. Adherent white discharge on the sidewalls of the vagina and cervix.	100
FIGURE 4.4 Wet mount microscopy (400x, phase contrast). A– Blastospores (culture positive for <i>C. krusei</i>) B– Hyphae and blastospores (culture positive for <i>C. albicans</i>)	100
FIGURE 4.5 Gram stain (1000x, oil immersion). A– Blastospores B– Hyphae and blastospores	101

FIGURE 5.1	A and B – Trichomonads seen with Gram stain (1000x, oil immersion).	114
FIGURE 5.2	“Strawberry cervix”.	119
FIGURE 5.3	Wet mount microscopy. A– Several trichomonads and inflammation (200x) B– Trichomonad with its typical structures: flagella on the outside and hydrogenosomes on the inside (400x) C– Several trichomonads, inflammation and bacterial vaginosis (400x, phase contrast)	119
FIGURE 6.1	Typical discharge associated with cytolytic vaginosis.	134
FIGURE 6.2	Cytolytic vaginosis. A– wet mount microscopy (400x, phase contrast) B– Gram stain (1000x, oil immersion); Pap smear (conventional) (400x)	135
FIGURE 6.3	Leptothrix seen in wet mount microscopy (400x, phase contrast). A– leptothrix and normal background microbiota B– leptothrix and <i>Candida</i> spp. blastospores	138
FIGURE 6.4	Leptothrix seen using Gram stain (1000x, oil immersion).	139
FIGURE 7.1	Severe aerobic vaginitis/desquamative inflammatory vaginitis. A– vaginal and cervical petechiae B– copious discharge C– vestibular involvement	146
FIGURE 7.2	Aerobic vaginitis/desquamative inflammatory vaginitis in wet mount microscopy (400x, phase contrast). A– moderate aerobic vaginitis B and C– severe aerobic vaginitis/desquamative inflammatory vaginitis	147
FIGURE 7.3	Aerobic vaginitis/desquamative inflammatory vaginitis aspects with Gram stain (1000x, oil immersion). Chains of cocci seen in A and B.	147
FIGURE 8.1	A and B - Colposcopic aspect of the vagina of a postmenopausal woman. Loss of vaginal rugae, petechiae, and easy bleeding.	159
FIGURE 8.2	Flowchart for the clinical assessment in suspected vaginal atrophy/atrophic vaginitis.	160
FIGURE 8.3	Wet mount microscopy (400x, phase contrast). A– vaginal atrophy B– atrophic vaginitis	161
FIGURE 8.4	Gram stain (1000x, oil immersion), vaginal atrophy. A– vaginal atrophy B– atrophic vaginitis	161
FIGURE 9.1	Wet mount microscopy (200x) from a prepubertal girls’ vagina. A– Exclusive presence of parabasal cells; lactobacilli absent B– Presence of inflammation in a case of bacterial vaginitis	174
FIGURE 9.2	Vulvar and perianal redness in a young girl with bacterial vaginitis (<i>S. pyogenes</i>).	177